CCL2 and neoplasm: Among the CCL2 inhibitors, immunomodulatory drugs (IMiDs), which include pomalidomide (NCT03257631), affect various molecular and cellular elements within the TME, and also the levels of various tumor-supporting cytokines, including CCL2, thus modulating monocytes, T cells and NK cells (Chanan-Khan et al., 2013).